Preclinical studies demonstrate that combining copper ionophores with anti-PD-L1 agents enhances tumor growth suppression in pancreatic ductal adenocarcinoma (PDAC), lung cancer, and HCC (Huang et al., 2023; Li P. et al., 2023; Zhou et al., 2019). Here, CD274 is linked to neoplasm.